Dr. Garg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 3rd Street
Cambridge, MA 02142Phone+1 617-732-5500
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 1993 - 1996- University of California San Francisco School of MedicineClass of 1993
Publications & Presentations
PubMed
- 31 citationsPhase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical TrialYaacov Frishberg, Georges Deschênes, Jaap W. Groothoff, Sally-Anne Hulton, Daniella Magen
Clinical Journal of the American Society of Nephrology. 2021-05-13 - 225 citationsEffects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D. Solomon, David Adams, Arnt V. Kristen, Martha Grogan, Alejandra González-Duarte
Circulation. 2019-01-22 - 8 citationsThe generalizability of observational data to elderly patients was dependent on the research question in a systematic reviewCary P. Gross, Pushkal P. Garg, Harlan M. Krumholz
Journal of Clinical Epidemiology. 2005-02-01
Press Mentions
FDA Approves Acoramidis, BridgeBio’s New ATTR-CM DrugNovember 23rd, 2024- Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with CardiomyopathySeptember 8th, 2022
- Patisiran Meets Primary Endpoint in Trial for ATTR Amyloidosis, CardiomyopathyAugust 4th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
